Ashley Losier, MD

New multi-center registry data confirm MAC as the dominant cause of NTM pulmonary disease, while culture conversion with standard therapy still fails in nearly half of patients.

Better risk stratification, more tolerable regimens, and outcome measures beyond culture conversion top the list of unmet needs Dr. Losier identifies for MAC and NTM pulmonary disease heading into ATS 2026.